https://orcid.org/0000-0002-2415-4659
Peer Review History
| Original SubmissionSeptember 16, 2024 |
|---|
|
Dear Dr. Guan, We are pleased to inform you that your manuscript 'NS1-mediated DNMT1 degradation regulates human bocavirus 1 replication and RNA processing' has been provisionally accepted for publication in PLOS Pathogens. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens. Best regards, Cary A. Moody Academic Editor PLOS Pathogens Alison McBride Section Editor PLOS Pathogens Michael Malim Editor-in-Chief PLOS Pathogens *********************************************************** Reviewer Comments (if any, and for reference): Reviewer's Responses to Questions Part I - Summary Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship. Reviewer #1: In this study, Qin et al. demonstrate that DNA methylation of the HBoV genome by DNMT1 regulates virus replication and viral gene expression. The authors have appropriately addressed all of the major points raised by reviewers in the first submission, going above and beyond by performing additional experiments to validate their model. These results have addressed the major concerns that were previously raised and improved the excitement of their findings. The overall findings of this study are applicable to understanding the epigenetic regulation of viral life cycles in general and parvovirus life cycle in particular. Reviewer #2: Dear Dr. Moody, As stated in my initial review I appreciate the opportunity to participate in the review of the Qin et al. manuscript (NS1-mediated DNMT1 degradation regulates human bocavirus 1 replication and RNA processing). Based on the results of the additional experiments and new insights into the mechanism associated with NS1-mediated DNMT1 degradation in human bocavirus 1 replication and RNA processing, I recommend and approve the manuscript for publication in Plospathogen. Strengths/Novelty/Significance: •Qin et al. utilized the HBoV model to characterize the role of DNA methylation in parvovirus DNA replication and RNA processing. •The study effectively characterized and showed that DNA methylation inhibition with 5-aza-2′-deoxycytidine (DAC) in HEK293T cells and Calu-3 cells coupled DNMT1 shRNA knockdown sufficiently revealed alteration in parvoviral DNA replication and RNA processing. •Similarly, DNA methylation inhibition with 5-aza-2′-deoxycytidine (DAC) in HEK293T cells and Calu-3 cells coupled DNMT1 shRNA knockdown indicated altered expression of NS1 and NP1 protein in addition to predominant NS1 cytoplasmic localization. •Immunoprecipitation of DNMT1 with NS1 added credence to the potential role of DNA methyltransferase in parvoviral gene expression and host-cell interaction. •The result provided evidence that NS1 expressed from the infectious clone pHBoV1-WH and epitope-tag construct (HA-NS1 and FLAG-NS1) modulated the DNMT1 depletion with restoration after MG132 treatment in a proteasome-dependent manner. •The study explores novel questions that have not been comprehensively explored in parvoviral biology and host-cell interaction, with potential implications for the advancement of parvoviral gene therapy. •This study will expand the frontiers of parvovirus and DNA viruses host cell interaction. Sincerely, Olufemi Fasina DVM, Ph.D., Diplomate. ACVP Assistant Professor Department of Veterinary Pathology 2720 College of Veterinary Medicine Iowa State University 515-294-5227 ********** Part II – Major Issues: Key Experiments Required for Acceptance Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions. Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject". Reviewer #1: None noted Reviewer #2: The weakness raised in the initial review have been addressed. ********** Part III – Minor Issues: Editorial and Data Presentation Modifications Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. Reviewer #1: None noted Reviewer #2: The editorial and data presentation modifications raised in the initial review have been addressed. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Olufemi Fasina DVM, Ph.D., Diplomate. ACVP |
| Formally Accepted |
|
Dear Dr. Guan, We are delighted to inform you that your manuscript, " NS1-mediated DNMT1 degradation regulates human bocavirus 1 replication and RNA processing ," has been formally accepted for publication in PLOS Pathogens. We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens. Best regards, Michael Malim Editor-in-Chief PLOS Pathogens |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .